I don't think the 0.5ml formulation (indeed it has the same active ingredient) has something that is patentable, it is quite obvious that a lower vol (less sterile water and mannitol) should cause less injection site pain. Teva clearly hopes to delay a generic to the 1ml product. Teva has another formulation - 40mg dose/three times a week for the same purpose.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.